DOI:
10.1055/s-00000134
Diabetologie und Stoffwechsel
LinksClose Window
References
Persson F, Nystrom T, Jorgensen ME. et al.
Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study.
Diabetes Obes Metab 2018;
20: 344-351
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.